Table 1.
Measures of β-cell function during hypeglycemic clamp and ratio to pretreatment in the groups of type 2 diabetic patients treated with exenatide or insulin glargine
| Pretreatment | End of treatment | Off-drug | End of treatment ratio to pretreatment (geometric mean) | End of treatment ratio to pretreatment (between group difference) | End of treatment ratio to pretreatment (P) | Off-drug ratio to pretreatment (geometric mean) | Off-drug ratio to pretreatment (between group difference) | Off-drug ratio to pretreatment (P) | |
|---|---|---|---|---|---|---|---|---|---|
| First-phase C-peptide response to glucose | |||||||||
| Glargine | 5.4 ± 0.6 | 6.1 ± 0.5 | 6.1 ± 0.6 | 1.17 ± 0.06 | 1.13 ± 0.05 | ||||
| Exenatide | 5.4 ± 0.6 | 9.4 ± 1.0 | 5.0 ± 0.6 | 1.78 ± 0.11 | 1.53 ± 0.11 | <0.0001 | 1.00 ± 0.05 | 0.90 ± 0.06 | 0.11 |
| Second-phase C-peptide response to glucose | |||||||||
| Glargine | 77.4 ± 8.8 | 80.7 ± 6.9 | 86.2 ± 9.1 | 1.08 ± 0.05 | 1.10 ± 0.05 | ||||
| Exenatide | 78.5 ± 8.3 | 235.6 ± 23.0 | 79.5 ± 9.1 | 3.05 ± 0.22 | 2.85 ± 0.22 | <0.0001 | 1.01 ± 0.04 | 0.92 ± 0.06 | 0.19 |
| C-peptide response to arginine at 15 mM glucose | |||||||||
| Glargine | 20.0 ± 2.5 | 24.8 ± 2.2 | 21.4 ± 2.5 | 1.31 ± 0.07 | 1.03 ± 0.08 | ||||
| Exenatide | 19.7 ± 2.1 | 62.2 ± 7.0 | 22.0 ± 2.6 | 3.19 ± 0.24 | 2.46 ± 0.20 | <0.0001 | 1.12 ± 0.06 | 1.08 ± 0.10 | 0.40 |
Data are means ± SD. Table adapted from Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ: One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 2009;32:762–768.